Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers



Status:Recruiting
Conditions:Blood Cancer, Lymphoma, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/15/2019
Start Date:April 28, 2017
End Date:June 30, 2021
Contact:Clinical Trials General Contact
Email:clinicaltrials@sunesis.com
Phone:6502663500

Use our guide to learn which trials are right for you!

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies

Phase 1b (Dose Escalation) in primarily CLL/SLL patients will evaluate safety and
pharmacology of self-administered twice a day oral doses beginning at 25 mg/dose for 4 weeks
with succeeding cohorts at escalating doses until establishing dose limiting toxicity or,
recommended Phase 2 dose. Patient data will be assessed before authorizing dose escalation
cohorts. Phase 2 (Cohort Expansion) will follow in cohorts using the recommended dose to
explore clinical activity, safety, pharmacology of SNS-062 (vecabrutinib) as monotherapy.

Phase 1b (Dose Escalation) This portion of the study will evaluate the safety and
pharmacology of a range of SNS-062 (vecabrutinib) dose levels administered to subjects with
previously treated B-lymphoid malignancies, including: chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL), lymphoplasmacytoid lymphoma/Waldenström's macroglobulinemia
(LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), diffuse large B-cell
lymphoma of the activated B-cell subtype (DLBCL-ABC), and follicular lymphoma (FL).

All subjects will self-administer SNS-062 orally BID. The dose-limiting toxicity (DLT) window
will be 4 weeks (1 cycle in length). Assessments on study will be performed in 4-week cycles.
Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels
of SNS-062 using a standard 3+3 dose-escalation design.

Based on the pattern of dose-limiting toxicities (DLTs) observed in the first cycle (4
weeks), escalation will proceed to define a maximum tolerated dose (MTD) and/or a recommended
dose (RD) that may be the MTD or a lower dose. An additional 6 subjects may be accrued at the
MTD or the RD to confirm SNS-062 safety and pharmacology as a prelude to further clinical
evaluation. Assessments regarding DLTs and dose escalation will be performed by a Safety
Review Committee (SRC) comprising, but not limited to, the principal investigators, the
medical monitor and the study sponsor drug safety representative.

Phase 2 (Cohort Expansion) This portion of the study provides cohort expansion to further
explore the clinical activity, safety, and pharmacology of SNS-062 monotherapy. Accrual will
occur independently for each of the 4 disease and mutation-specific cohorts. Subjects will
self-administer SNS-062 orally at the RD of SNS-062 identified in the Phase 1b portion of the
study. The SRC will meet regularly to assess the efficacy and safety for each cohort.

Inclusion Criteria (Key factors listed):

- Eastern Cooperative Oncology Group Performance Status of ≤2.

- Confirmed malignancy with relapsed/refractory disease after ≥2 lines of standard
systemic therapy including prior BTK inhibitor therapy having CLL, LPL/WM, MCL or MZL
and for DLBCL-ABC and FL, after ≥2 lines of standard systemic therapy.

- Presence of measurable disease through various assessments depending on specific
cancer type.

- Current medical need for therapy of the B-lymphoid malignancy due to disease-related
symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or PD.

Exclusion Criteria (Key factors listed):

- Active central nervous system involvement.

- History of second primary malignancy that has progressed or required systemic
treatment in the past 2 years. Exceptions include: local cancers of the skin, cervix
or breast cancers, non-invasive bladder cancer, hormone sensitive prostate cancer with
stable PSA ≥3 months, and other localized solid tumors in situ/other low risk cancers.

- Significant cardiovascular disease or electrocardiogram (ECG) abnormalities

- Ongoing risk for bleeding due to bleeding diathesis, platelet function disorder,
uncontrolled peptic ulcer disease, oral anticoagulation medications.

- Evidence of uncontrolled systemic bacterial, fungal or viral infections at the start
of drug therapy.

- Demonstrated intolerance to BTK inhibitor as shown by discontinuation due to adverse
effects.

- Use of a moderate or strong inhibitor or inducer of CYP3A4 within 7 days prior to
start of study therapy (e.g., some antibiotics, antifungals, anticonvulsants,
grapefruit).
We found this trial at
8
sites
Houston, Texas 77030
Phone: 713-792-3530
?
mi
from
Houston, TX
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Phone: 617-632-5497
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
New York, New York 10065
Phone: 646-962-9414
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Phone: 646-888-1319
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
101 The City Drive South
Orange, California 92868
714-456-7890
Phone: 877-827-8839
University of California, Irvine Medical Center We are UC Irvine Health. We are a devoted...
?
mi
from
Orange, CA
Click here to add this to my saved trials
San Diego, California 92093
Phone: 858-822-6281
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Seattle, Washington 98104
Phone: 206-215-2363
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida 33617
Phone: 813-745-2591
?
mi
from
Tampa, FL
Click here to add this to my saved trials